
TOI Stock Forecast & Price Target
TOI Analyst Ratings
Bulls say
Oncology Institute Inc. is poised for significant financial growth as its partnership with Helios is expected to enhance margins, transitioning to a more favorable cost structure in 2026 and 2027. With an anticipated return to margins of 12%-15% as contracts mature and increasing focus on value-based care, the company is well-positioned for sustainable earnings growth, which is likely to drive stock performance over time. Furthermore, the robust expected growth in dispensing revenue, particularly following the establishment of a new pharmacy in California and the elimination of the DIR fee, supports a healthier profitability profile and increased margin visibility moving forward.
Bears say
The Oncology Institute Inc. has experienced contract losses in 2024, adversely affecting gross margins, and a series of new contracts launching later in 2024 and early 2025 are anticipated to exert additional pressure as they scale. The company’s revenue growth from patient services is likely constrained, with trends indicating flat or low single-digit growth, significantly lagging behind the industry average of 11-14%. Furthermore, the business faces potential challenges from increased drug prices and changes in payer partnerships, which could further compress margins and impede the company’s ability to achieve break-even EBITDA by late 2025.
This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.
TOI Analyst Forecast & Price Prediction
Start investing in TOI
Order type
Buy in
Order amount
Est. shares
0 shares